bioRxiv Cancer Biology· Das, G. M., Oturkar, C. C., Park, J. H., Adams, C., Ijaz, I., Oshi, M., Dolan, M., Caradori, A., Zhang, Y., Wang, J., Boleslav, B., Mager, D., Nair, A., Samanta, T., Jung, K. H., Han, S. Y., Yang, S., Tiwari, A., Mishra, R., Ebos, J., Attwood, K., Takabe, K., Kaipparettu, B. A. ·· 16 hours agoScore63
Tamoxifen and Doxorubicin Synergistically Target Estrogen Receptor beta-Mutant p53-p73 Axis, a Therapeutically Actionable Vulnerability in Triple Negative Breast Cancer
In brief
Das et al., using genetic and pharmacological approaches, showed that tamoxifen synergizes with doxorubicin in triple negative breast cancer (TNBC). Tamoxifen enhances the interaction between ER beta and mutant p53, disrupting the p73-mutant p53 complex, reactivating p73, and inducing apoptosis and ferroptosis, which inhibits tumor growth in mutant p53 CDX and PDX models. The study provides preclinical rationale for repurposing tamoxifen combined with doxorubicin in molecularly stratified TNBC. DOI: 10.64898/2026.10.21.760572v1.
Source: bioRxiv Cancer Biology · biorxiv.org